Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma

Ariceum Therapeutics United Kingdom United States of America Germany

View original content:https://www.prnewswire.co.uk/news-releases/ariceum-therapeutics-granted-uk-authorisation-to-conduct-phase-i-clinical-study-of-its-first-in-class-iodine-123-labelled-parp-inhibitor-in-patients-with-recurrent-glioblastoma-302074584.html